Intellia Therapeutics Inc
NTLA
Market Cap$860.77M
Close$
$-5.18
162.3% downside
Current Fair Value
162.3% downsideOvervalued by 162.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $860.77 Million |
|---|---|
| Enterprise Value | $873.81 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.25 |
| Beta | 2.13 |
| Outstanding Shares | 103,500,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.64 |
|---|---|
| PEG | -25.49 |
| Price to Sales | - |
| Price to Book Ratio | 1.19 |
| Enterprise Value to Revenue | 19.18 |
| Enterprise Value to EBIT | -1.65 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...